Advanced, metastatic or recurrent pembrolizumab |
Low |
February 2024 |
Bladder/Urothelial locally advanced or metastatic avelumab |
Medium cycle 1-4 Low cycle 5 on if patient tolerates |
February 2025 |
Bladder intravesical BCG (OncoTICE) |
Low |
August 2024 |
Bladder intravesical gemcitabine |
High |
August 2024 |
Bladder intravesical mitomycin |
High |
February 2027 |
Bladder intravesical mitomycin single dose post TURBT |
High |
February 2025 |
Bladder/Urothelial adjuvant ddMVAC (dose dense methotrexate vinBLASTine DOXOrubicin cISplatin) |
Medium |
August 2024 |
Bladder/Urothelial adjuvant or neoadjuvant ciSplatin and gemcitabine |
Medium Day 1. Low day 8 |
February 2025 |
Bladder/Urothelial fluorouracil and mitomycin chemoradiation |
Medium2 Day 1. Low Day 22# |
August 2024 |
Bladder/Urothelial locally advanced definitive cISplatin (weekly) chemoradiation |
Medium# |
August 2025 |
Bladder/Urothelial locally advanced or metastatic cARBOplatin and gemcitabine (Day 1 cARBOplatin) |
Medium Day 1. Low day 8 |
August 2024 |
Bladder/Urothelial locally advanced or metastatic cISplatin and gemcitabine |
Medium Day 1. Low day 8 |
August 2024 |
Bladder/Urothelial metastatic MVAC (methotrexate vinBLASTine DOXOrubicin cISplatin) |
Medium |
August 2024 |
Bladder/Urothelial neoadjuvant ddMVAC (dose dense methotrexate vinBLASTine DOXOrubicin cISplatin) |
Medium |
August 2024 |
Bladder/Urothelial small cell cARBOplatin and etoposide |
Medium |
August 2025 |
Bladder/Urothelial small Cell cISplatin and etoposide |
Medium |
August 2025 |
Urothelial upper tract adjuvant cARBOplatin and gemcitabine |
Medium day 1 Low day 8 |
August 2023 |